Aspire BioPharma, Inc. (ASBP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aspire BioPharma, Inc. (ASBP) has a cash flow conversion efficiency ratio of -0.785x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.04 Million) by net assets ($3.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Aspire BioPharma, Inc. for the company's overall valuation and market capitalisation.
Aspire BioPharma, Inc. - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Aspire BioPharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aspire BioPharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aspire BioPharma, Inc. ranked by their cash flow conversion efficiency. Explore Aspire BioPharma, Inc. cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sedania Innovator Bhd
KLSE:0178
|
0.056x |
|
Globe Kita Terang Tbk PT
JK:GLOB
|
-0.003x |
|
Plurilock Security Inc
V:PLUR
|
0.390x |
|
Energoinstal S.A.
WAR:ENI
|
-0.034x |
|
Companhia de Fiacao e Tecidos Cedro Cachoeira
SA:CEDO3
|
0.099x |
|
Iconic Minerals Ltd
V:ICM
|
-0.323x |
|
elumeo SE
XETRA:ELB
|
0.087x |
|
Rigsave S.P.A.
XETRA:H68
|
N/A |
Annual Cash Flow Conversion Efficiency for Aspire BioPharma, Inc. (2021–2025)
The table below shows the annual cash flow conversion efficiency of Aspire BioPharma, Inc. from 2021 to 2025. View ASBP live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.38 Million | $-4.92 Million | 0.772x | +348.43% |
| 2024-12-31 | $-1.54 Million | $-265.19K | 0.172x | +616.19% |
| 2023-12-31 | $19.58 Million | $-653.11K | -0.033x | -584.45% |
| 2022-12-31 | $289.07 Million | $-1.41 Million | -0.005x | -100.89% |
| 2021-12-31 | $-475.00 | $-260.00 | 0.547x | -- |
About Aspire BioPharma, Inc.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually admi… Read more